The Food and Drug Administration on Wednesday approved Rebyota for adults who have trouble fighting off infections with Clostridium difficile, commonly referred to as C. diff, a bacteria that causes nausea, cramping and diarrhea.The infection is particularly dangerous when it reoccurs and is linked to about 15,000 to 30,000 deaths a year.But the proliferation of stool banks and fecal transplant practitioners across the country has created regulatory headaches for the FDA, which doesn’t traditionally regulate doctors’ medical procedures.Abortion rights groups look to next fights after 2022 winsChina eases some virus controls, searches pedestriansDrug slows Alzheimer's but can it make a real difference?US officials say 2 more places will test sewage for polioThe FDA said it approved the treatment based on results from two studies in which 70% of patients taking Rebyota saw their symptoms resolve after eight weeks, compared with 58% of patients getting a placebo."